Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.57 |
| ▸ | HTT | P42858 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | RAF1 | P04049 | 6/20 | 0.48 |
| ▸ | MEN1 | O00255 | 7/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4239060 | 0.90 | RAF1 (0.59) | MAPTSMN1; SMN2ALDH1A1RAF1 | |
| SCHEMBL936531 | 0.90 | MAPK14 (0.54) | MAPTHTTLMNAHSP90AA1RECQL | |
| SCHEMBL4238737 | 0.86 | RAF1 (0.67) | MAPTHTTLMNAHSP90AA1RECQL | |
| SCHEMBL4244346 | 0.85 | MAPT (0.69) | MAPTHTTLMNAHSP90AA1RECQL | |
| SCHEMBL937860 | 0.81 | RAF1 (0.56) | MAPTHTTLMNAMAPK14SMN1; SMN2 | |
| SCHEMBL4243012 | 0.80 | SMN1; SMN2 (0.57) | MAPTHTTLMNAMAPK14SMN1; SMN2 | |
| SCHEMBL1492785 | 0.79 | PSEN1 (0.57) | MAPTHTTLMNAHSP90AA1RECQL | |
| SCHEMBL4251022 | 0.78 | MAPT (0.65) | MAPTHTTLMNAHSP90AA1RECQL | |
| SCHEMBL939518 | 0.78 | RAF1 (0.75) | MAPK14RAF1 | |
| SCHEMBL5006752 | 0.77 | MAPK14 (0.57) | MAPTLMNAMAPK14SMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1616865-A1 | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas | Bayer Pharmaceuticals Corporation (US) | 2006-01-18 | — | — | EP | claimed |
| EP-1042305-B1 | INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | BAYER PHARMACEUTICALS CORP (US) | 2005-06-08 | — | — | EP | claimed |
| US-20040102636-A1 | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas | BAYER CORPORATION | 2004-05-27 | — | — | US | claimed |
| US-7517880-B2 | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-04-14 | — | — | US | disclosed |
| US-20090093526-A1 | INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | BAYER HEALTHCARE LLC | 2009-04-09 | — | — | US | disclosed |
| EP-1539121-A4 | METHODS OF PROMOTING OSTEOGENESIS | SCIOS INC (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1545535-A4 | TREATMENT OF PAIN BY INHIBITION OF P38 MAP KINASE | SCIOS INC (US) | 2008-06-04 | — | — | EP | disclosed |
| US-20080108658-A1 | METHODS OF PROMOTING OSTEOGENESIS | PROTTER ANDREW A | 2008-05-08 | — | — | US | disclosed |
| EP-1583535-A4 | METHODS FOR TREATING DIABETES | SCIOS INC (US) | 2008-03-19 | — | — | EP | disclosed |
| US-20080039461-A1 | Treatment of pain by inhibition of p38 map kinase | PROTTER ANDREW A | 2008-02-14 | — | — | US | disclosed |
| US-7268139-B2 | Methods of promoting osteogenesis | SCIOS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| WO-2004019873-A9 | METHODS OF PROMOTING OSTEOGENESIS | SCIOS INC (US) | 2004-06-24 | — | — | WO | disclosed |
| US-20040122008-A1 | Treatment of pain by inhibition of p38 MAP kinase | SCIOS, INC. | 2004-06-24 | — | — | US | disclosed |
| US-20040102636-A1 | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas | BAYER CORPORATION | 2004-05-27 | — | — | US | disclosed |
| WO-2004024083-A2 | METHODS OF BONE HEALING | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2004-03-25 | — | — | WO | disclosed |
| WO-2004021988-A2 | TREATMENT OF PAIN BY INHIBITION OF P38 MAP KINASE | SCIOS INC. (US) | 2004-03-18 | — | — | WO | disclosed |
| WO-2004019873-A2 | METHODS OF PROMOTING OSTEOGENESIS | SCIOS INC. (US) | 2004-03-11 | — | — | WO | disclosed |
| EP-1042305-A4 | INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | BAYER AG (US) | 2003-05-14 | — | — | EP | disclosed |
| EP-1042305-A1 | INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | Bayer Corporation (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999032463-A1 | INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093526-A1 | INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | MAP2K2, MAPK1, MAP2K1 | MAPT 618/4885HTT 3084/4885LMNA 4398/4885 |
| US-20040102636-A1 | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas | MAP2K2, MAPK1, MAP2K1 | MAPT 618/4885HTT 3084/4885LMNA 4398/4885 |
| US-20080108658-A1 | METHODS OF PROMOTING OSTEOGENESIS | MAPK1, BMP2, MAPK3 | MAPT 4179/4885HTT 4699/4885LMNA 3940/4885 |
| US-20040122008-A1 | Treatment of pain by inhibition of p38 MAP kinase | OPRK1, OPRL1, MAPK3 | MAPT 1172/4885HTT 3332/4885LMNA 2824/4885 |
| US-20080039461-A1 | Treatment of pain by inhibition of p38 map kinase | OPRK1, OPRL1, MAPK3 | MAPT 1172/4885HTT 3332/4885LMNA 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.